Drugs / BN101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04930562 | Apr 2021 → Jun 2022 | chronic graft versus host disease | BioNova Pharmaceuticals (Shanghai) LTD. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BN101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04930562 ↗ |
| Action | Inhibit | “BN101 is an orally ROCK2 selective inhibitor” NCT04930562 ↗ |
| Target | ROCK2 | “BN101 is an orally ROCK2 selective inhibitor” NCT04930562 ↗ |